本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Recursion Pharmaceuticals, Inc.

5.32
-0.5900-9.98%
盤後5.29-0.0300-0.56%18:36 EDT
成交量:5,995.92萬
成交額:3.37億
市值:23.10億
市盈率:-2.95
高:6.20
開:6.04
低:5.30
收:5.91
52周最高:12.36
52周最低:3.79
股本:4.34億
流通股本:4.15億
量比:1.14
換手率:14.45%
股息:- -
股息率:- -
每股收益(TTM):-1.8042
每股收益(LYR):-1.6909
淨資產收益率:-86.34%
總資產收益率:-39.08%
市淨率:2.51
市盈率(LYR):-3.15

資料載入中...

2025/10/10

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/09/25

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson 擬減持10萬股,總價約47.6萬美元
2025/09/10

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/08/29

重要事件披露

Form 8-K/A - Current report: [Amend]
2025/08/26

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson擬減持10萬股,總價約48.4萬美元
2025/08/18

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals高管 Khan Najat擬減持36599股,總價約20.2萬美元
2025/08/11

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals 高管 Christopher Gibson 擬減持617875股,總價約326.2萬美元
2025/08/05

重要事件披露

Form 8-K - Current report
2025/08/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/07/08

重要事件披露

Form 8-K - Current report
2025/06/18

重要事件披露

Form 8-K - Current report
2025/06/10

重要事件披露

Form 8-K - Current report
2025/05/09

重要事件披露

Form 8-K - Current report
2025/05/05

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/05/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/05

重要事件披露

Form 8-K - Current report
2025/03/27

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson Christopher擬減持138574股,總價約83.7萬美元
2025/03/18

重要事件披露

Form 8-K - Current report
2025/03/06

關聯方擬減持公告

Form 144 | Recursion Pharmaceuticals高管Gibson擬減持20000股,總價約127,400美元
2025/03/05

關聯方擬減持公告

Form 144 | RECURSION PHARMACEUTICALS高管 Christopher Gibson擬減持20000股,總價約131600美元